Education and Training
Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole
The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Letrozole
- drug: Anastrozole
Eligibility
Inclusion Criteria:
- Current height less than 5th percentile AND/OR
- Predicted adult height (based on bone age) more than 10 cm below target height (mid
parental height)
- Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and
testosterone > 15 ng/dl
Exclusion Criteria:
- Bone age reading more than 14.0 years
- Follicle stimulating hormone > 20 IU/L
Ages Eligible for Study
10 Years - 17 Years
Genders Eligible for Study
Male
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
E Kirk Neely, MD
650-723-5791
Not Recruiting